Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
Public ClinicalTrials.gov record NCT04884035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma
Study identification
- NCT ID
- NCT04884035
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 224 participants
Conditions and interventions
Conditions
Interventions
- CC-220 Drug
- CC-99282 Drug
- Cyclophosphamide Drug
- Doxorubicin Drug
- Polatuzumab vedotin Drug
- Prednisone Drug
- Rituximab Drug
- Vincristine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 14, 2021
- Primary completion
- Nov 30, 2028
- Completion
- Nov 30, 2028
- Last update posted
- Apr 16, 2026
2021 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 162 | Birmingham | Alabama | 35233 | Not yet recruiting |
| Mayo Clinic - Arizona | Scottsdale | Arizona | 85259 | Recruiting |
| Local Institution - 169 | Duarte | California | 91010 | Not yet recruiting |
| Mayo Clinic - Jacksonville | Jacksonville | Florida | 32224 | Withdrawn |
| Mayo Clinic Jacksonville - PPDS | Jacksonville | Florida | 32224 | Recruiting |
| Local Institution - 161 | Marietta | Georgia | 30060 | Not yet recruiting |
| University Of Kansas Medical Center | Kansas City | Kansas | 66160 | Recruiting |
| Cancer Center Of Kansas-Wichita | Wichita | Kansas | 67214 | Recruiting |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905-0001 | Recruiting |
| HealthPartners Cancer Research Center | Saint Louis Park | Minnesota | 55426 | Recruiting |
| University of Nebraska - Fred and Pamela Buffet Center | Omaha | Nebraska | 68198 | Recruiting |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | Withdrawn |
| Local Institution - 170 | Charlotte | North Carolina | 28204 | Not yet recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77003 | Recruiting |
| Local Institution - 168 | Murray | Utah | 84107 | Not yet recruiting |
| Local Institution - 171 | St. George | Utah | 84790 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04884035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04884035 live on ClinicalTrials.gov.